Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03434379 · OUTCOME

Maximum Serum Concentration (Cmax) of Atezolizumab in the China Population

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma · Source last updated 2023-10-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
mcg/mL
Interval / dispersion
Standard Deviation
Time frame
Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)

Analysis population: The China PK-evaluable population was defined as all participants in the China population who received any dose of study treatment and who had at least one post-baseline PK sample available.

Groups in this outcome

Atezolizumab + Bevacizumab - China

Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab + Bevacizumab - China85

Reported measurements

Source class 1
Values in mcg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Atezolizumab + Bevacizumab - China456153Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        153
        value
        456
denoms
  1. counts
    1. group Id
      OG000
      value
      85
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
    id
    OG000
    title
    Atezolizumab + Bevacizumab - China
param Type
MEAN
population Description
The China PK-evaluable population was defined as all participants in the China population who received any dose of study treatment and who had at least one post-baseline PK sample available.
reporting Status
POSTED
time Frame
Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)
title
Maximum Serum Concentration (Cmax) of Atezolizumab in the China Population
type
SECONDARY
unit Of Measure
mcg/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice